Merck to start studying lower dose of HIV drug after FDA hold

20.09 2022: Merck & Co Inc said on Tuesday it would start fresh late-stage studies of its HIV treatment, islatravir, months after the U.S. Food and Drug Administration put the trials on hold, citing safety concerns…
Similar articles